restructuring plan, page-14

Look, one would imagine if Inavir is successfully on the market in Japan (and market leading antiviral), that there is a likely market elsewhere. And even if we have been overtaken by Favipiravir and it will hit the market first, it is still a twice daily x 5 day (10 dose) drug, versus 1 single dose treatment of LANI, so given all Pros and Cons, LANI still has an opportunity to shine.

Other Asian markets - China is a smouldering fire waiting to ignite, given their population size and their lack of hygiene standards at many levels - but their economic growth is massive. One would imagine that their CFDA would be open to discussion. Even allowing for their third world status, this is a massive market.

The next Flu pandemic will revitalise interest and I believe there are still lobbying opportunities for Biota - they need to start to play it smart...time for Plumb the salesman to kick into gear.